The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

THE United States Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences' lenacapavir, a drug to be injected twice annually, for preventing HIV infection in adults and adolescents at ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

The US Food and Drug Administration has approved lenacapavir (Yeztugo), the first twice-yearly injectable HIV-1 prevention ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.